Cell & Gene: The Podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
- Update frequency
- every 13 days
- Average duration
- 25 minutes
- Episodes
- 116
- Years Active
- 2021 - 2025
Focus Areas For Cell Therapy With Bristol Myers Squibb's Stephan Krause, Ph.D.
We love to hear from our listeners. Send us a message.
In June 2023, PDA held its Advanced Therapy Medicinal Products Conference in Baltimore, MD. At the conference, Stephan Krause, Ph.D., Executive D…
The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault
We love to hear from our listeners. Send us a message.
Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA tech…
Inside Prime Editing with Prime Medicine's Dr. Andrew Anzalone
We love to hear from our listeners. Send us a message.
Dr. Andrew Anzalone, Head of the Prime Editing Platform and Scientific Co-Founder of Prime Medicine joins Cell & Gene: The Podcast to talk with H…
Navigating CMC Challenges with Parenteral Drug Association's Glenn Wright
We love to hear from our listeners. Send us a message.
Glenn Wright, President and CEO of Parenteral Drug Association (PDA), sat down with Cell & Gene: The Podcast's Erin Harris at the 2023 PDA ATMP c…
An Interview with Dr. Usman "Oz" Azam
We love to hear from our listeners. Send us a message.
Dr. Usman "Oz" Azam is CEO of Inspirna now but has spent much of his career in the cell and gene therapy space dedicating years as Novartis’ Glob…
Targeting Oncogenic Drivers for Solid Tumor Cancers with Affini-T Therapeutics' Dr. Jak Knowles
We love to hear from our listeners. Send us a message.
Affini-T Therapeutics combines a validated TCR discovery platform with synthetic biology switches to attack tumor biology at its root cause. Co-F…
TJU's Jefferson Institute for Bioprocessing's Impact on CGT with Parviz Shamlou
We love to hear from our listeners. Send us a message.
Parviz Shamlou, Vice President and Executive Director at Thomas Jefferson University joins Cell & Gene: The Podcast to talk to Host Erin Harris a…
Computational Biology's Role In Gene Therapy With Kriya Therapeutics' Dr. Shankar Ramaswamy
We love to hear from our listeners. Send us a message.
Shankar Ramaswamy, M.D., CEO & Co-Founder, Kriya Therapeutics joins Cell & Gene: The Podcast's Erin Harris for a discussion on the evolving role …
The Near-Term Future of Exosome Science with Capricor Therapeutics' Dr. Linda Marbán
We love to hear from our listeners. Send us a message.
Dr. Linda Marbán, Ph.D., CEO of Capricor Therapeutics, a clinical-stage biotech focused on the development of cell and exosome-based therapeutics…
Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon
We love to hear from our listeners. Send us a message.
In December 2022, Atara Biotherapeutics’ Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV…
The Potential of RNA Exon Editing with Ascidian Therapeutics' Romesh Subramanian, Ph.D.
We love to hear from our listeners. Send us a message.
Cell & Gene: The Podcast Host, Erin Harris, welcomes Romesh Subramanian, Ph.D., CEO of Ascidian Therapeutics, a Boston-based biotech focused on r…
Automating Processes to Scale CGT Manufacturing with PA Consulting's Paolo Siciliano
We love to hear from our listeners. Send us a message.
When it comes to manufacturing, many cell and gene therapy companies struggle to automate the diverse processes needed to scale manufacturing. Lo…
The Why Behind In-House Manufacturing With Sangamo's Andy Ramelmeier
We love to hear from our listeners. Send us a message.
On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Andy Ramelmeir, EVP Head of Technical Operations at Sangamo Therapeutics, …
2023 Market Outlook with AdBio and ISCT's Miguel Forte
We love to hear from our listeners. Send us a message.
Miguel Forte is Entrepreneur in Residence at AdBio, a VC firm based in France, and President Elect of ISCT. Forte and Cell & Gene: The Podcast ho…
CMC and Scale Up with Mustang Bio's Robert Sexton
We love to hear from our listeners. Send us a message.
MustangBio's Robert Sexton, VP Program and Alliance Leadership, explains the why behind the need for this role in any CGT company. Having worked …
An Interview with Dr. Peter Marks
We love to hear from our listeners. Send us a message.
Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA) sits down with…
Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth
We love to hear from our listeners. Send us a message.
Shoreline Biosciences' Chief Scientific Officer Dr. Robert Hollingsworth shares his insight on intelligently designed allogeneic off-the-shelf, s…
The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg
We love to hear from our listeners. Send us a message.
BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical T…
Manufacturing at the Point of Care with Orgenesis' CEO Vered Caplan
We love to hear from our listeners. Send us a message.
Orgenesis' CEO, Vered Caplan explains the business model behind providing cell and gene therapies that may be manufactured at the point of care. …
Capstan Therapeutics' CEO Laura Shawver on In Vivo Cell Engineering
We love to hear from our listeners. Send us a message.
Capstan Therapeutics' CEO, Laura Shawver, Ph.D., talks us through the company's in vivo CAR therapies and what led to the in vivo cell engineerin…